Sign in

    Richard Adcock

    Chief Executive Officer at Immunitybio Inc
    Board
    Since October 20, 2020
    Age
    56 years
    Education
    Holds a Bachelor of Science in Business Administration from Northern State University and an MBA in Healthcare Management from the University of Phoenix.
    Tenure
    Joined IBRX as Chief Executive Officer on October 20, 2020 and was later appointed President and Board member in March 2021.

    Also at Immunitybio Inc

    PS
    Patrick Soon-Shiong
    Executive Chairman of the Board
    DS
    David Sachs
    Chief Financial Officer (CFO)

    About

    Richard Adcock is a seasoned executive in the healthcare industry, currently serving as the Chief Executive Officer of IBRX since October 2020, and is 56 years old as of April 29, 2025.

    He holds a Bachelor of Science in Business Administration from Northern State University and an MBA in Healthcare Management from the University of Phoenix, forming the foundation of his extensive career in healthcare management.

    Prior to IBRX, he held pivotal roles including Global Engineering Director at GE Healthcare, and executive positions at Sanford Health and Verity Health System, demonstrating his expertise in operational leadership and strategic innovation. His appointment as President and Board member in March 2021 further reflects his significant contributions to organizational growth.

    $IBRX Performance Under Richard Adcock

    Past Roles

    OrganizationRoleDate RangeDetails
    ImmunityBio, Inc. (IBRX) Board Member March 2021 Former role held at IBRX
    ImmunityBio, Inc. (IBRX) President N/A Former role held at IBRX
    Verity Health System of California, Inc. Chief Executive Officer January 2018 - September 2020 Steered the organization through a restructuring event
    Sanford Health Chief Innovation Officer / President / Executive Vice President / Director 2004 - 2017 Held various leadership roles
    GE Healthcare Global Engineering Director N/A N/A

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Salary$802,123 AnnualBase salary for 2024 including any salary increases
    Stock Awards$2,396,341 457,317 RSUs awarded on February 22, 2024 vesting in three equal annual installments (33.33%, 33.33%, 33.34%) Grant date fair value of RSUs
    Option Awards$7,214,767 1,591,463 options granted on February 22, 2024 vesting in three equal annual installments (33.33%, 33.33%, 33.34%) Exercise price $5.24 per share
    All Other Compensation$64,044 As applicableIncludes $14,045 for 401(k) contributions and $49,999 for life insurance premium reimbursements with tax neutrality

    Performance Compensation

    Data from  FY 2024

    Performance Compensation: Non-Equity Incentive Plan Compensation for 2024

    ComponentDescription/ValueDetails
    Target Bonus Opportunity$597,000 Calculated as 75% of the annual base salary of $796,000
    Actual Bonus Payout$477,600 Achieved at 80.0% of the target bonus based on performance metrics
    Performance MetricsN/AIncludes categories: Financing, Regulatory & Product, Clinical Development, Commercial Readiness, and Human Capital
    Evaluation PeriodFiscal Year 2024 Performance measured for the 2024 period
    Vesting/PaymentNo vesting schedule; cash award paid in 2025 Contingent upon achievement of performance metrics and continued employment
    Grant DateFebruary 22, 2024 Applies to the performance compensation framework
    Grant Date Stock Price$5.24 per share Provided for reference though not applicable to the cash award
    Bonus ParametersNo threshold or cap definedThe bonus plan did not specify a maximum payout